News

Filter

Zeltia diversifying its business pharma model to finance R&D pipeline

22-07-2014

PharmaMar, biopharmaceutical company which represents the main affiliate of Spanish Grupo Zeltia is diversifying…

AplidinBiotechnologyChugai PharmaceuticalGP PharmLicensingOncologyPharmaMarPM 1183PolitrateResearchZeltia

Japan NHI price listing for Chugai’s Kadcyla delayed

14-11-2013

Japanese drugmaker Chugai Pharmaceutical, which is majority owned by Swiss major Roche, says that the…

Asia-PacificChugai PharmaceuticalKadcylaOncologyPharmaceuticalPricingResearchRoche

Roche and Chugai’s SC RoActemra improves RA long term

Roche and Chugai’s SC RoActemra improves RA long term

28-10-2013

Roche and its majority-owned Japanese subsidiary Chugai Pharmaceutical have announced that their RoActemra…

Anti-Arthritics/RheumaticsAsia-PacificChugai PharmaceuticalPharmaceuticalResearchRoActemraRoche

Chugai in co-development accord for obinutuzumab with Nippon Shinyaku

28-11-2012

Japanese drugmaker Chugai Pharmaceutical (TYO: 4519), which is majority-owned by Swiss drug major Roche…

BiotechnologyChugai PharmaceuticalLicensingNippon ShinyakuobinutuzumabOncologyPharmaceuticalResearchrituximabRoche

Chugai first to establish stable cell lines of cancer stem cells

22-10-2012

Chugai Pharmaceutical (TYO: 44519), which is majority-owned by Swiss drug major Roche (ROG: SIX), has…

Chugai PharmaceuticalOncologyPharmaceuticalResearchRoche

Chugai expands in Singapore, opening second satellite research institute

17-07-2012

Chugai Pharmabody Research (CPR), a unit of Swiss pharma major Roche (ROG: SIX) majority-owned Japanese…

Asia-PacificChugai PharmaceuticalFinancialPharmaceuticalResearchRoche

COMPANY SPOTLIGHT

Menarini

Back to top